Advanced Coronary Heart Disease (CHD)

1. Definition and Pathophysiology

• Left main coronary artery disease (LMCAD) - stenosis ≥50% in the left main trunk, threatening perfusion of the majority of LV myocardium
• Three-vessel disease (3VD) - obstructive stenoses in all three major epicardial arteries (LAD, LCx, RCA)
• Two-vessel disease with proximal LAD involvement - significant stenosis of the proximal LAD plus one other vessel
• Chronic total occlusion (CTO) - complete obstruction of one or more vessels
• LV systolic dysfunction (EF <35-40%) from ischemic cardiomyopathy

• Goldman-Cecil Medicine, p. 632

2. Clinical Presentation

• Stable exertional angina (classic) - graded by CCS class
• Dyspnea, fatigue, and reduced exercise tolerance as anginal equivalents, particularly in elderly patients (>80 years) and diabetics
• Asymptomatic/silent ischemia - common with sedentary lifestyle or autonomic neuropathy
• Acute coronary syndromes (NSTEMI, STEMI) when a vulnerable plaque ruptures
• Ischemic heart failure - reduced EF from repeated ischemia or infarction

3. Risk Stratification and Diagnosis

Noninvasive Testing

• Braunwald's Heart Disease, p. (Braunwald's block 13)

Invasive Assessment

• Invasive coronary angiography (ICA) is recommended for patients with stable chest pain and obstructive CAD who have moderate-to-severe ischemia despite guideline-directed medical therapy (GDMT)
• FFR (fractional flow reserve) or iFR (instantaneous wave-free ratio) is recommended for patients referred for ICA without prior stress testing to determine hemodynamic significance of lesions
• A CCTA-defined stenosis ≥50% in the left main, FFR-CT ≤0.80, or severe stenosis ≥70% in all 3 main vessels warrants ICA for therapeutic decision-making
• Fuster and Hurst's The Heart, 15th ed.

4. Comprehensive Medical Management

4a. Disease-Modifying Pharmacotherapy (Mortality Benefit)

• Ezetimibe added to statins further reduces events in post-ACS patients even when LDL is 50-100 mg/dL
• PCSK9 inhibitors (evolocumab, alirocumab) can reduce LDL by ~60%, effective for residual elevated LDL despite statins ± ezetimibe
• Icosapent ethyl (IPE) - pure EPA omega-3 - significantly reduces cardiovascular death, MI, and stroke when added to statins in patients with well-controlled LDL but elevated triglycerides (135-500 mg/dL)

• In patients with type 2 diabetes: SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) or GLP-1 receptor agonists (e.g., semaglutide, liraglutide) reduce cardiac events independently
• Goldman-Cecil Medicine, p. 632-633

4b. Anti-Anginal / Anti-Ischemic Therapy (Symptom Benefit, No Mortality Benefit in Stable CHD)

5. Revascularization: PCI vs. CABG

When to Revascularize

• Medically refractory angina - for symptom relief
• Left main CAD or three-vessel disease (regardless of LV function) - to prolong life
• Proximal LAD involvement (any number of vessels) - may prolong life
• Diabetic patients with 2-3 vessel disease - reduces composite death/MI/stroke vs. medical therapy; reduces CV events and death

• Symptomatic angina - for symptom relief
• Does not reduce death, MI, or major cardiovascular events when added to optimal medical therapy as initial management in stable ischemic heart disease
• Not indicated for purely anatomical stenosis in the absence of ischemia symptoms

PCI vs. CABG Comparison

• Fuster and Hurst's The Heart, 15th ed.

6. Refractory Angina

Options for Refractory Angina

• Fuster and Hurst's The Heart, 15th ed.
• Goldman-Cecil Medicine

7. Special Populations

Elderly (>65-80 years)

• Atypical presentations (dyspnea, fatigue) are common; silent ischemia more prevalent
• Standard risk scores (Framingham, Pooled Cohort Equations) don't apply above age 80
• ISCHEMIA and PROMISE trials support conservative management with OMT as a reasonable first approach
• Revascularization decisions must weigh frailty, comorbidities, and patient preference

Diabetics

• CABG is preferred over PCI for multivessel disease
• SGLT2 inhibitors and GLP-1 agonists provide additional CV risk reduction
• Higher risk for silent ischemia, larger infarcts, and worse post-PCI outcomes

Advanced CHD with Heart Failure (Ischemic Cardiomyopathy)

• Revascularization (particularly CABG) should be considered in patients with HF and viable myocardium (hibernating myocardium)
• STICH trial extended follow-up (10 years) showed CABG + OMT reduced all-cause mortality vs. OMT alone in patients with EF ≤35%
• Cardiac MRI and PET viability imaging guide revascularization decisions

HIV and Advanced CHD

• HIV patients have significantly higher MI rates even after controlling for traditional risk factors; inflammation and immune activation drive accelerated atherosclerosis
• Dyslipidemia management requires awareness of statin-antiretroviral drug interactions: simvastatin is contraindicated with protease inhibitors; fluvastatin is safer but needs lower starting dose
• HIV is now counted as a major cardiovascular risk factor for primary prevention decisions
• Goldman-Cecil Medicine, p. 3729

8. Secondary Prevention - Summary Targets

Recent Evidence (2024-2026)

• A 2025 meta-analysis on CT angiography (PMID: 40758074) confirmed that advanced CCTA analyses (CT-FFR, pericoronary fat attenuation, plaque characteristics) significantly predict future cardiac events beyond conventional angiographic stenosis severity.
• A 2025 systematic review and meta-analysis (PMID: 40472168) on antithrombotic therapy in patients with oral anticoagulation + stabilized CAD found that single antithrombotic therapy (OAC alone) was associated with lower bleeding risk without significantly increasing ischemic events compared to dual therapy.
• A 2026 network meta-analysis (PMID: 41145110) comparing drug-coated balloons (DCB) vs. drug-eluting stents (DES) for coronary lesions supports second-generation or newer DES as the preferred option for most lesions.

1. Advanced CHD is best managed with intensive secondary prevention as the foundation - statins, antiplatelet therapy, ACE-I/ARB, and lifestyle modification.
2. CABG is life-prolonging in left main, three-vessel, and proximal LAD disease, and is the preferred revascularization strategy in diabetics with multivessel disease.
3. PCI improves symptoms but does not reduce hard endpoints in stable CHD when added to optimal medical therapy.
4. Refractory angina (despite maximal therapy) can be palliated with EECP, spinal cord stimulation, or the coronary sinus reducer device.
5. Ischemic cardiomyopathy with viable myocardium benefits from revascularization (particularly CABG) for mortality reduction.